Belimumab for systemic lupus erythematosus: a practice-based view.
- Published in:
- Lupus, 2013, v. 22, n. 4, p. 372, doi. 10.1177/0961203313476154
- By:
- Publication type:
- Article
Works matching IS 09612033 AND DT 2013 AND VI 22 AND IP 4
Results: 8
1
2
Minimising steroids in lupus nephritis – will B cell depletion pave the way?
- Published in:
- Lupus, 2013, v. 22, n. 4, p. 390, doi. 10.1177/0961203313476155
- By:
- Publication type:
- Article
3
B-cell-directed therapies in systemic lupus erythematosus – where do we stand?
- Published in:
- Lupus, 2013, v. 22, n. 4, p. 341, doi. 10.1177/0961203312473360
- By:
- Publication type:
- Article
4
B cell biology: implications for treatment of systemic lupus erythematosus.
- Published in:
- Lupus, 2013, v. 22, n. 4, p. 342, doi. 10.1177/0961203312471576
- By:
- Publication type:
- Article
5
Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
- Published in:
- Lupus, 2013, v. 22, n. 4, p. 361, doi. 10.1177/0961203312471575
- By:
- Publication type:
- Article
6
Rituximab treatment in lupus nephritis – where do we stand?
- Published in:
- Lupus, 2013, v. 22, n. 4, p. 381, doi. 10.1177/0961203312471574
- By:
- Publication type:
- Article
7
Epratuzumab for Systemic Lupus Erythematosus*.
- Published in:
- Lupus, 2013, v. 22, n. 4, p. 400, doi. 10.1177/0961203312469692
- By:
- Publication type:
- Article
8
The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus.
- Published in:
- Lupus, 2013, v. 22, n. 4, p. 350, doi. 10.1177/0961203312469453
- By:
- Publication type:
- Article